diclofenac has been researched along with hydrochlorothiazide in 23 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (4.35) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 9 (39.13) | 29.6817 |
2010's | 13 (56.52) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Faller, B; Wohnsland, F | 1 |
Anacardio, R; Aureli, L; Cesta, MC; Cruciani, G; De Simone, L; Moriconi, A | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Avdeef, A; Tam, KY | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Gribnau, FW; Koopmans, PP; Thien, T | 1 |
Bhagat, K | 1 |
Barceló, D; Jelić, A; Petrović, M | 1 |
Egberts, AC; Grouls, RJ; Jansen, PA; Korsten, EH; van der Linden, CM; van Marum, RJ | 1 |
Chu, KR; Jeong, SH; Lee, E; Park, ES | 1 |
Kelemen, A; Kónya, Z; Pintye-Hódi, K; Regdon, G; Sipos, B; Sovány, T | 1 |
Csicsák, D; Takács-Novák, K; Völgyi, G | 1 |
1 review(s) available for diclofenac and hydrochlorothiazide
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for diclofenac and hydrochlorothiazide
Article | Year |
---|---|
The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Clinical Trials as Topic; Creatinine; Diclofenac; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Ibuprofen; Indenes; Male; Middle Aged; Potassium; Renin; Sulindac | 1987 |
Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Diclofenac; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Ibuprofen; Lisinopril; Middle Aged; Osteoarthritis; Sulindac; Treatment Outcome | 2001 |
20 other study(ies) available for diclofenac and hydrochlorothiazide
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
Topics: Alkanes; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Octanols; Permeability; Pharmaceutical Preparations; Solubility; Water | 2001 |
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Chemical Phenomena; Chemistry, Physical; Humans; In Vitro Techniques; Interleukin-8; Models, Molecular; Phenylpropionates; Protein Binding; Quantitative Structure-Activity Relationship; Serum Albumin; Stereoisomerism | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Multi-residue method for trace level determination of pharmaceuticals in solid samples using pressurized liquid extraction followed by liquid chromatography/quadrupole-linear ion trap mass spectrometry.
Topics: Acetaminophen; Atorvastatin; Chromatography, Liquid; Diclofenac; Geologic Sediments; Heptanoic Acids; Hot Temperature; Hydrochlorothiazide; Ibuprofen; Pharmaceutical Preparations; Pyrroles; Reference Standards; Reproducibility of Results; Rivers; Sewage; Solid Phase Extraction; Tandem Mass Spectrometry | 2009 |
Recurrence of adverse drug reactions following inappropriate re-prescription: better documentation, availability of information and monitoring are needed.
Topics: Adverse Drug Reaction Reporting Systems; Aged, 80 and over; Diclofenac; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydrochlorothiazide; Medication Errors; Middle Aged; Secondary Prevention | 2010 |
Effect of particle size on the dissolution behaviors of poorly water-soluble drugs.
Topics: Chemistry, Pharmaceutical; Crystallization; Diclofenac; Hydrochlorothiazide; Ibuprofen; Kinetics; Models, Chemical; Particle Size; Solubility; Solvents; Surface Properties; Technology, Pharmaceutical; Water | 2012 |
Physicochemical characterisation and investigation of the bonding mechanisms of API-titanate nanotube composites as new drug carrier systems.
Topics: Atenolol; Calorimetry, Differential Scanning; Diclofenac; Diltiazem; Drug Carriers; Drug Liberation; Hydrochlorothiazide; Microscopy, Electron, Scanning; Nanotubes; Solubility; Spectroscopy, Fourier Transform Infrared; Surface Properties; Thermogravimetry; Titanium | 2017 |
Right filter-selection for phase separation in equilibrium solubility measurement.
Topics: Chemistry Techniques, Analytical; Chemistry, Pharmaceutical; Diclofenac; Filtration; Hydrochlorothiazide; Hydrogen-Ion Concentration; Kinetics; Membranes, Artificial; Papaverine; Progesterone; Solubility | 2018 |